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Abstract: Granulocyte-macrophage colony-stimulating factor (GM-CSF) and inteleukin-3 (IL-3) have
long been known as mediators of emergency myelopoiesis, but recent evidence has highlighted their
critical role in modulating innate immune effector functions in mice and humans. This new wealth
of knowledge has uncovered novel aspects of the pathogenesis of a range of disorders, including
infectious, neoplastic, autoimmune, allergic and cardiovascular diseases. Consequently, GM-CSF
and IL-3 are now being investigated as therapeutic targets for some of these disorders, and some
phase I/II clinical trials are already showing promising results. There is also pre-clinical and clinical
evidence that GM-CSF can be an effective immunostimulatory agent when being combined with
anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4) in patients with metastatic melanoma
as well as in novel cancer immunotherapy approaches. Finally, GM-CSF and to a lesser extent IL-3
play a critical role in experimental models of trained immunity by acting not only on bone marrow
precursors but also directly on mature myeloid cells. Altogether, characterizing GM-CSF and IL-3 as
central mediators of innate immune activation is poised to open new therapeutic avenues for several
immune-mediated disorders and define their potential in the context of immunotherapies.
Keywords: GM-CSF; IL-3; innate immunity; sepsis; experimental autoimmune encephalomyelitis;
rheumatoid arthritis; allergy; atherosclerosis; inflammatory bowel diseases; cancer immunotherapy;
trained immunity
1. Introduction
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and inteleukin-3 (IL-3) are
hematopoietic factors that belong to the β common ([βc]/CD131) family of cytokines together with
IL-5 and KK34 (the latter has been identified in some species but its ortholog is a pseudogene in
humans and mice) [1]. While the effects of IL-5 are mainly restricted to eosinophils [2,3], GM-CSF and
IL-3 exert a broader role on the modulation of the innate immune response by engaging heterodimeric
receptors composed of a shared βc subunit and a specific α subunit (CD116 for GM-CSF, CD123 for
IL-3) that signal through the JAK2-STAT5 pathway as well as other kinases [1]. Their role in steady-state
hematopoiesis is dispensable (except for the development/maintenance of alveolar macrophages of
which absence leads to pulmonary alveolar proteinosis, non-lymphoid tissue dendritic cells (DCs)
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and functional maturation of natural killer T cells) [4–10]. GM-CSF and IL-3 promote emergency
myelopoiesis (i.e., generation and differentiation of myeloid cells upon infection or in the context of
inflammation) [9,11,12] and also modulate effector functions of several innate immune cell subsets
in vitro and in vivo [1,13–21]. Of note, preliminary results of clinical trials have shown that blocking
antibodies against GM-CSF and IL-3-specific receptor α subunits or βc subunits can be safe and
effective in several autoimmune or inflammatory diseases [1,22]. This wealth of evidence has spurred
renewed interest in evaluating the immunomodulatory potential of GM-CSF and IL-3 on the innate
immune system and its therapeutic implication. In this review, we will summarize the biology of
GM-CSF and IL-3 focusing on their role in the modulation of innate immune effector functions,
the mechanistic relevance of GM-CSF and IL-3 in the development and progression of infectious,
autoimmune and inflammatory disorders and how this new wave of knowledge is paving the way for
novel therapeutic approaches (Figure 1 and Table 1).
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Figure 1. GM-CSF and IL-3 in immune-mediated diseases. Diseases in which a role for GM-CSF, IL-3 
or both has been described are respectively indicated in blue, yellow or mixed blue/yellow boxes. Pre-
clinical and clinical studies support an important role for GM-CSF in the pathogenesis of pulmonary 
alveolar proteinosis, cardiovascular diseases (myocardial infarction, Kawasaki disease, myocarditis, 
and acute rheumatic fever) and inflammatory bowel disease. Interestingly, GM-CSF is an effective 
immunostimulatory agent in the context of cancer immunotherapy. Both GM-CSF and IL-3 play 
pivotal roles in the development and progression of allergic asthma, aortic dissection, atherosclerosis 
and sepsis. While the role of GM-CSF in rheumatoid arthritis and multiple sclerosis has been firmly 
established, the relevance of IL-3 in the pathogenesis of these disorders is more controversial. There 
is also evidence of IL-3 involvement in lupus nephritis. Finally, IL-3 acts as a survival factor in several 
hematologic malignancies and is currently under investigation, together with its specific receptor 
subunit CD123 as therapeutic target. 
Figure 1. GM-CSF and IL-3 in i e-mediate diseases. Diseases in which a role for GM-CSF,
IL-3 or b t been described a respectively indicated in blue, yellow or mixed blue/yellow boxes.
Pre-clinical and clini l t i s s pport an important role for GM-CSF in the pathogenesis of pulmonary
alveolar proteinosis, cardiovascular diseases ( yocardial infarction, Kawasaki disease, myocarditis,
and acute rheumatic fever) and inflammatory bowel disease. Interestingly, GM-CSF is an effective
immunostimulatory agent in the context of cancer immunotherapy. Both GM-CSF and IL-3 play
pivotal roles in the development and progression of allergic asthma, aortic dissection, atherosclerosis
and sepsis. While the role of GM-CSF in rheumatoid arthritis and multiple sclerosis has been firmly
established, the relevance of IL-3 in the pathogenesis of these disorders is more controversial. There is
also evidence of IL-3 involvement in lupus nephritis. Finally, IL-3 acts as a survival factor in several
hematologic malignancies and is currently under investigation, together with its specific receptor
subunit CD123 as therapeutic target.
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2. Biology of GM-CSF and IL-3
GM-CSF and IL-3 are produced by several hematopoietic (e.g., lymphocytes) and
non-hematopoietic (e.g., epithelial cells, and fibroblasts) cell subsets [1]. In particular, the cellular
source can vary depending on the inducing stimulus and the experimental model. For example,
airway epithelial cells challenged with allergenic stimuli produce GM-CSF, which in turn leads to
allergic sensitization [23–25]. In human and murine models of multiple sclerosis (experimental
autoimmune encephalomyelitis, EAE), GM-CSF is mainly produced by polarized T cells and memory
B lymphocytes [16,26–31]. Although retinoic acid receptor (RAR)-related orphan receptor (ROR)
γt-expressing T cells (e.g., Th17 lymphocytes) can produce GM-CSF [26,27], some groups have
reported the STAT5-dependent expression of this cytokine by a specialized subset of T cell [29–31].
In addition, T cell expression of GM-CSF and IL-3 is specifically regulated by the transcription factor
Bhlhe40 of which deletion does not reduce IFNγ or IL-17 production but impairs the induction of
EAE [32,33]. GM-CSF is also expressed by T cells upon stimulation with IL-23 and plays a critical
role in experimental models of T cell-dependent colitis [18,34]. IL-3 is produced by T cells upon
activation and in particular under Th2 polarizing conditions such as allergic inflammation and parasitic
infestation [35–37]. For example, thymic stromal lymphopoietin (TSLP)-activated DCs induce T cell
production of IL-3, which plays a crucial role in basophil recruitment [35]. Another important source
of GM-CSF and IL-3 is represented by innate immune cells. Type 3 innate lymphoid cells (ILC3s)
are a major source of GM-CSF in the gut where it is required to modulate mononuclear phagocyte
effector functions and induce the differentiation of regulatory T cells in the steady-state [38]. On the
contrary, IL-23-induced GM-CSF production by ILC3s plays a critical role in the pathogenesis of
ILC-driven colitis [39]. Innate response activator (IRA) B cells are a subset of B1a-derived B cells that
produces GM-CSF and IL-3 in infection and atherosclerosis models, thereby modulating myeloid cell
differentiation and maturation [11,40–42]. Finally, basophils are both the target and the source of IL-3,
which also act in an autocrine manner to modulate basophil survival and cytokine production [19,20].
Beyond their contribution to emergency myelopoiesis, GM-CSF and IL-3 exert a prominent
role in host defense and inflammation by modulating effector functions of mature myeloid cells.
Cell specificity depends on the expression of specific receptor subunits: both GM-CSF and IL-3 can
modulate monocytes, macrophages and eosinophils; GM-CSF also acts on neutrophils, while IL-3
is a potent regulator of basophil, mast cell and plasmacytoid DC activities [1,13–21]. The target
cell subset also depends on the experimental model investigated, but in general GM-CSF and IL-3
contribute to ongoing inflammation by promoting cell survival, proliferation or activation. For example,
GM-CSF unlocks a pro-inflammatory program in monocytes and their progeny and therefore plays
an essential role in the pathogenesis of EAE [16]. Of note, GM-CSF and IL-3 also activate human
monocytes. In combination with IL-4, they promote monocytes differentiation into DCs with Th2 and
Th1 polarizing properties, respectively, for IL-3 and GM-CSF [43,44]. In addition, they promote the
expression of CCL17 alone or in combination with IL-4 and enhance LPS-induced TNF-α production
in in vitro models of trained immunity [13–15,45,46]. It is also worth mentioning that, in some
experimental models, GM-CSF has shown an anti-inflammatory effect [17,38,47,48], highlighting the
context-specific role of GM-CSF and IL-3 in inflammation.
IL-3 specific receptor subunit CD123 is overexpressed in many hematological malignancies,
including leukemic stem-like cells of patients with acute myeloid leukemia (AML) [49–52], progenitor
cells of chronic myeloid leukemia (CML) [53], blastic plasmacytoid dendritic cell neoplasm
(BPDCN) [54,55], neoplastic mast cells and systemic mastocytosis [56,57]. Of note, CD123 expression
in AML correlates with reduced patient survival, supporting the therapeutic targeting of CD123 in this
disease [49–52,54,58–62].
3. GM-CSF and IL-3 in Sepsis
Sepsis is defined as a life-threatening organ dysfunction syndrome caused by a dysregulated host
response to infection [63]. GM-CSF and IL-3 play a central role in the pathogenesis of sepsis and might
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also be exploited for diagnostic or therapeutic purposes. In a cecal ligation and puncture (CLP) murine
model of sepsis, GM-CSF produced by IRA B cells enhances bacterial clearance and exerts a protective
role [40]. Several experimental studies in murine models of sepsis have pointed to a key role for
GM-CSF in increasing survival, and therefore GM-CSF has also been tested as an immunostimulating
adjuvant therapy in patients with sepsis. Unfortunately and at variance with murine data, clinical
results have been inconclusive so far [64]. GM-CSF treatment does not significantly impact 28-day
mortality but improves clinical endpoints in selected patient populations. For example, in patients with
non-traumatic abdominal sepsis who underwent surgical intervention, GM-CSF treatment significantly
decreased the hospital length of stay, duration of antibiotic therapy and infectious complications [65].
Another study found that GM-CSF treatment in patients with severe sepsis and respiratory dysfunction
improved gas exchange (which indicates a reduced number of alveolar neutrophils) and increased
function of pulmonary phagocytes and circulating neutrophils [66]. Several reasons may account for
the failure of GM-CSF treatment to decrease mortality in sepsis patients. First, most of the studies
were underpowered to evaluate survival and only assessed 28-day mortality; in addition, GM-CSF
treatment might be of limited use across all patient populations but can result beneficial in specific
subsets of patients, thereby highlighting the importance of proper patient stratification; finally, timing
and modalities of GM-CSF treatment should be harmonized across clinical trials in order to make
results more comparable. Since GM-CSF treatment has not been associated with significant adverse
effects so far, a large prospective multi-center with standardized GM-CSF administration to sepsis
patients with the aim of stratifying patients and disease states is warranted to define a possible role for
GM-CSF immunostimulating adjuvant therapy in sepsis management.
The role of IL-3 in sepsis has been less intensively investigated compared to that of GM-CSF.
Interestingly, IL-3 has recently been implicated in the pathogenesis of CLP-induced acute sepsis by
promoting myelopoiesis and cytokine storm. Genetic deletion or antibody-mediated blockade of
IL-3 activity protects mice from sepsis. Of note, high plasma levels of IL-3 in sepsis patients are
associated with increased mortality [11]. The recent development of a point-of-care platform for rapid
and sensitive detection of IL-3 in human blood samples has further confirmed that increased IL-3
plasma levels are associated with high organ failure rates and holds promises for implementing the
use of IL-3 as a biomarker of sepsis in the clinical setting [67].
4. GM-CSF and IL-3 in Autoimmune and Allergic Diseases
Several studies have reported a prominent role for GM-CSF and to a lesser extent IL-3 in
autoimmune diseases, and for some of them such as multiple sclerosis (MS) [68] and rheumatoid
arthritis (RA) [69,70], humanized blocking antibodies are now being evaluated in clinical trials.
GM-CSF genetic deletion or blockade impairs the development of, while GM-CSF administration
or transgenic expression in T cells exacerbates EAE [26,27,71–73]. Of note, GM-CSF expression is
a marker of encephalitogenic CD4+ T cells in both mice and humans [26,27,29–31]. However, GM-CSF
expression in MS is not a unique feature of CD4+ T cells since it is also produced by memory B cells [28].
Mechanistically, it has been proposed that GM-CSF acts on monocytes to promote the expression of
a pathogenic program characterized by genes linked to inflammasome function, phagocytosis and
chemotaxis [16]. GM-CSF is currently under investigation as a therapeutic target in patients with
MS and a phase Ib clinical trial using a recombinant human anti-GM-CSF antibody has been recently
completed [68]. Encephalitogenic CD4+ T cells also express IL-3. However, conflicting results exist on
the role of this cytokine in the development and progression of EAE [31,74,75].
Similarly to EAE, GM-CSF deficiency or neutralization prevents disease progression in murine
models of arthritis, whereas GM-CSF administration leads to symptoms exacerbation [76–79].
Mechanistically, T cell-derived GM-CSF increases chronic inflammation but is dispensable for arthritis
initiation. On the other hand, stromal cells and synovial ILCs represent the main source of GM-CSF [80].
Importantly, GM-CSF levels are increased in synovial fluid of RA patients [81], and a phase IIb clinical
trial using a recombinant human anti-GM-CSF antibody in patients with moderate-to-severe RA has
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shown decreased disease activity [70]. More controversial is the role of IL-3 in arthritis, which has been
reported to either attenuate [82] or exacerbate symptoms [83].
IL-3 plays a central role in modulating basophil and mast cell expansion and activity in the context
of type 2 (allergic) responses [84,85]. Th2 lymphocytes secrete IL-3 that expand and recruit basophils,
which in turn reinforce Th2 polarization [35–37]. Basophil-derived cytokines (e.g., IL-4 and IL-13) can
also promote monocyte and macrophage alternative activation [15,86]. Importantly, IL-3-deficient mice
do not develop airway hyperresponsiveness (AHR) in a model of allergic airway inflammation induced
by systemic injections of ovalbumin (OVA) adsorbed onto alum adjuvant and followed by intranasal
OVA challenge. Adoptive transfer of IL-3-differentiated basophils restores AHR [19]. GM-CSF also
contributes to the development of allergic airway inflammation upon intranasal sensitization with
dust mites. In these models, airway epithelial cells release GM-CSF that, together with other cytokines
(e.g., IL-33), promotes the activation of lung CD11b+ DCs and the ensuing development of Th2
immunity [23–25]. Finally, eosinophils (hallmark cell of allergic inflammation) [87] can be activated
not only by IL-5 but also by GM-CSF and IL-3 [18,21,88,89]. As such, therapeutic strategies aimed at
targeting GM-CSF or βc are currently under investigation for the treatment of asthma [1].
Finally, administration of exogenous IL-3 or an anti-IL-3-blocking antibody to MRL/lpr mice (which
develops a spontaneous autoimmune disease that resembles human systemic lupus erythematosus) has
shown a prominent role for IL-3 in the pathogenesis and progression of lupus nephritis [90].
5. GM-CSF and IL-3 in Cardiovascular Diseases
The immune system is regarded as a major player in the development and progression
of cardiovascular diseases [91–97], including atherosclerosis, myocardial infarction (MI), dilated
cardiomyopathies, myocarditis, hypertension, Kawasaki disease (KD), aortic dissection and acute
rheumatic fever. In some of these conditions, a prominent role for GM-CSF and/or IL-3 has also
been shown. Several lines of evidence support the notion that GM-CSF exerts a pro-atherogenic
role. Ldlr−/− Csf2−/− mice develop smaller lesions [98], whereas exogenous administration of
GM-CSF to atherosclerotic mice stimulates intimal cell proliferation and promotes the development
of atherosclerosis plaques [99,100]. Interestingly, IRA B cells expand in atherosclerosis and play
a pathogenetic role by producing GM-CSF that promotes DC generation and differentiation of
IFNγ-secreting Th1 cells [42]. GM-CSF and IL-3 also promote extramedullary hematopoiesis and
differentiation of monocytes that infiltrate and aggravate atherosclerotic lesions [101].
Genetic deletion or antibody-mediated blockade of GM-CSF increases survival following MI by
reducing inflammation and leukocyte accrual and promoting wound healing. Mechanistically, GM-CSF
is produced by cardiac fibroblast shortly after MI, elicits chemokine production in the infarcted tissue
(which in turn promotes neutrophil and monocyte recruitment) and also enhances myelopoiesis by
acting on a specific βc-expressing progenitor cell population [102]. Collectively, these findings suggest
that GM-CSF exerts a detrimental role in the context of MI.
GM-CSF production by cardiac fibroblast has also been implicated in the pathogenesis of KD,
a systemic vasculitis of the childhood that particularly affects coronary arteries and therefore represents
a leading cause of pediatric heart disease in developed countries [103]. In a mouse model of KD elicited
by Candida albicans water-soluble fraction (CAWS), GM-CSF is rapidly produced by cardiac fibroblast
upon CAWS challenge and stimulates cytokine and chemokine production by resident macrophages,
thereby promoting cardiac inflammation. Interestingly, antibody-mediated GM-CSF blockade prevents
the development of cardiac inflammation [104].
Group A streptococcus (GAS) infection can lead to a delayed autoimmune response known as
acute rheumatic fever (ARF) that can also involve the heart causing autoimmune-drive rheumatic
heart disease. Recently, it was reported that peripheral blood mononuclear cells isolated from ARF
patients and stimulated in vitro with GAS produce more CD4+ T cell-derived GM-CSF compared to
healthy controls [105]. It is tempting to speculate that CD4+ T cell-derived GM-CSF plays a role in the
pathogenesis of ARF. Further studies are required to confirm this hypothesis.
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Table 1. Involvement of GM-CSF and IL-3 in disease pathogenesis.
Disease Cytokine Involved Description References
Pulmonary alveolar proteinosis GM-CSF Decreased bioavailability of GM-CSF leads to impaired maturation of alveolar macrophages and accumulation ofsurfactant and related products within lung alveoli. [4,6–8]
Myocardial infarction GM-CSF GM-CSF produced by cardiac fibroblasts promotes inflammation and leukocyte accrual and impairs wound healingupon myocardial infarction. [102]
Kawasaki disease GM-CSF GM-CSF produced by cardiac fibroblasts stimulates cytokine and chemokine production by resident macrophages,thereby promoting cardiac inflammation. [104]
Myocarditis GM-CSF IL-23-induced, CD4+ T cell-derived GM-CSF drives cardiac inflammation in an experimental model of myocarditis. [97]
Acute rheumatic fever GM-CSF PBMCs isolated from acute rheumatic fever patients and stimulated in vitro with GAS produce more CD4
+ T
cell-derived GM-CSF compared to healthy controls. [105]
Inflammatory bowel disease GM-CSF
The role of GM-CSF in IBD is context dependent. IL-23-induced GM-CSF drives the pathogenesis of T cell-driven and
ILC-driven experimental models of colitis. DSS-induced epithelial damage is exacerbated in GM-CSF deficient mice.
Adoptive transfer of GM-CSF-treated murine monocytes ameliorates T cell-dependent experimental colitis.
[17,18,34,47,48,106,107]
Lupus nephritis IL-3
Administration of exogenous IL-3 and an anti-IL-3-blocking antibody to MRL/lpr mice (which develop a spontaneous
autoimmune disease that resembles human systemic lupus erythematosus), respectively, promotes and restrains lupus
nephritis progression.
[90]
Hematologic malignancies IL-3 IL-3 is a survival factor for several malignant hematopoietic cell lineages, especially acute myeloid leukemia whereCD123 expression on cancer cells correlates with reduced patient survival. [49–51]
Allergic asthma GM-CSF and IL-3
Epithelial cell-derived GM-CSF promotes DC activation and Th2 immunity in an experimental model of dust
mite-elicited allergic airway inflammation. Basophil-derived IL-3 induces the development of AHR in a model of allergic
airway inflammation induced by systemic injections of OVA/alum followed by intranasal OVA challenge.
[19,23–25]
Multiple sclerosis GM-CSF and IL-3
GM-CSF promotes the development of EAE by inducing the expression of a pathogenic program in monocytes. GM-CSF
can be produced by both CD4+ T cells and memory B cells. Encephalitogenic CD4+ T cells also express IL-3. However,
conflicting results exist on the role of this cytokine in the development and progression of EAE.
[16,26–31,71–75]
Aortic dissection GM-CSF and IL-3
IL-3 elicits macrophage production of MMP12 and is required for the development of chemically induced thoracic aortic
aneurysm and dissection. GM-CSF synergizes with aortic inflammation elicited by CaCl2 and Ang II to induce aortic
dissection/intramural hematoma.
[95,96]
Atherosclerosis GM-CSF and IL-3 Both GM-CSF and IL-3 aggravate atherosclerosis development by promoting formation of atherosclerotic plaques,extramedullary hematopoiesis and monocyte differentiation, DC generation and Th1 polarization. [42,98–101]
Sepsis GM-CSF and IL-3 In experimental models of CLP-induced sepsis, GM-CSF produced by IRA B cells enhances bacterial clearance and exertsa protective role. Conversely, IL-3 promotes myelopoiesis and cytokine storm therefore playing a detrimental role. [11,40]
Rheumatoid arthritis GM-CSF and IL-3 GM-CSF derived from ILCs, stromal and T cells plays a prominent role in the development and progression of murinemodels of arthritis. IL-3 has been reported to either attenuate or exacerbate arthritis symptoms. [76–80,82,83]
Abbreviations: AHR, airway hyperresponsiveness; Ang II, angiotensin II; CLP, cecal ligation and puncture; DC, dendritic cell; DSS, dextran sulfate sodium; EAE, experimental autoimmune
encephalomyelitis; GAS, group A streptococcus; IBD, inflammatory bowel disease; ILCs, innate lymphoid cells; IRA B cells, innate response activator B cells; MMP12, matrix metalloprotease
12; OVA, ovalbumin; PBMCs, peripheral blood mononuclear cells.
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6. GM-CSF and IL-3 in Inflammatory Bowel Diseases (IBDs)
IL-23-induced GM-CSF drives the pathogenesis of T cell-driven and ILC-driven experimental
models of colitis [18,34,106]. GM-CSF promotes skewing of hematopoietic stem and progenitor
cells towards toward granulocyte-monocyte progenitors and also their accumulation in spleen and
colon [34]. Interestingly, eosinophils have been identified as a critical effector cell subset of the
IL-23/GM-CSF axis in colitis. Mechanistically, GM-CSF promotes eosinophil accumulation in the
gut and their activation, which leads to the release of toxic mediators like eosinophil peroxidase and
the ensuing tissue damage [18]. Nevertheless, the role of GM-CSF in IBDs is also context-dependent,
as DSS-induced epithelial damage is exacerbated in GM-CSF deficient mice [47,48,107], and adoptive
transfer of GM-CSF-treated murine monocytes ameliorates T cell-dependent experimental colitis [17].
Several reports in Crohn’s disease (CD) and ulcerative colitis (UC) patients indicate disruption of
GM-CSF signaling due to increased circulating or local levels of anti-GM-CSF autoantibodies [108–110],
downregulation of CD116 [111] or inactivating mutations of βc [112,113]. Although these results point
to a protective role for GM-CSF, clinical trials of recombinant GM-CSF administration to CD patients
have failed to demonstrate induction of remission [114]. Further studies are required to define the
mechanistic role of GM-CSF in IBDs and whether its blockade or administration may be beneficial in
specific patient populations.
7. GM-CSF and IL-3 in Cancer Therapy
GM-CSF is highly expressed in the milieu of several cancers and has been variably associated
with pro- or anti-tumorigenic functions [115,116]. One of the first attempts to use GM-CSF as a therapy
for experimental cancer models consisted in treating mice with autologous cancer cells transduced
with GM-CSF [117]. Although this approach proved extremely successful in mice, phase 3 clinical trials
using GM-CSF-transduced irradiated tumor cells failed to demonstrate clinical efficacy and hampered
further development of this approach [118]. However, the recent success of immune checkpoint
inhibitors for treatment of hematologic and solid tumors [119–121] has sparked renewed interest in
the use of GM-CSF as a component of combination therapy. Accordingly, combining GM-CSF to the
anti-CTLA-4-blocking antibody Ipilimimab increases the efficacy of the latter in patients with metastatic
melanoma [122]. GM-CSF is also expressed by the oncolytic virus talimogene laherparecvec (T-VEC),
a modified herpes simplex virus approved for local treatment of non-resectable melanoma [123].
Recently, biomaterial-based vaccination systems encapsulating GM-CSF, TLR agonists (e.g., CpG) and
autologous irradiated cancer cells alone or in combination with immune checkpoint inhibitors have
shown promising results in experimental cancer models [124–128]. These new approaches are likely to
redefine the use of GM-CSF in the context of cancer immunotherapy.
IL-3 is a survival factor for several malignant hematopoietic cell lineages. As such, IL-3 or
its specific receptor subunit CD123 has been investigated as therapeutic targets, especially in
AML where CD123 expression on cancer cells correlates with reduced patient survival [49–51].
Therapeutic strategies tested so far include CD123-directed CAR T cells, IL-3-toxin conjugates and
anti-CD123 that can act by blocking IL-3 pro-survival signaling and also promoting NK cell-mediated
antibody-dependent cell-mediated cytotoxicity [52,54,58–62].
8. GM-CSF and IL-3 in Trained Immunity
A growing body of literature shows that priming of the innate immune system with microbial of
inflammatory stimuli can have a long-term impact on the subsequent response to secondary stimuli,
a phenomenon referred to as innate immune memory or trained immunity [129,130]. This concept has
also been fostered by clinical evidence that live attenuated vaccines exert heterologous (“non-specific”)
effects, potentially protecting against unrelated pathogens and having positive effects on survival
that are substantially greater than those accounted for by protection against the target disease [131].
In vitro and in vivo experimental models have shown that innate immune cell stimulation with pattern
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recognition receptor ligands or cytokines can induce trained immunity [14,46,132–146]. Recently,
an in vivo model ofβ-glucan-induced trained immunity has shown a remarkable effect on myelopoiesis
that was at least in part dependent on GM-CSF activity on bone marrow precursors [143]. GM-CSF
also enhances the response to β-glucan in an in vitro experimental model of trained immunity [46].
Interestingly, we have shown that GM-CSF and IL-3 can directly modulate subsequent responses of
human monocytes to LPS in in vitro models of trained immunity. In particular, in a short-term model
of trained immunity (priming with GM-CSF or IL-3 and LPS stimulation the following day), GM-CSF
and IL-3 enhance LPS-induced TNF production at the post-transcriptional level by modulating p38
and nicotinamide adenine dinucleotide (NAD)-dependent sirtuin 2 (SIRT2) activities. Conversely,
in a long-term model of trained immunity (priming with GM-CSF or IL-3 followed by 6 days of resting
and then LPS stimulation), GM-CSF and IL-3 enhance LPS-induced TNF production by promoting
monocyte renewal and increase in cell number in a c-Myc-dependent manner [14]. Altogether,
these results point to an important role for GM-CSF (and possibly also IL-3) in trained immunity and
also open new ways of understanding its mechanism of action in vitro and in vivo.
9. Conclusions
Although the role of GM-CSF and IL-3 in mediating emergency myelopoiesis has been known
for a long time, they are now considered critical modulators of the innate immune response by acting
directly on mature immune cells. As such, they have been implicated in the pathogenesis of a range of
diseases and are now been investigated as immunostimulating agents in cancer therapy (Figure 1).
In addition, uncovering their role as mediators of innate immune memory has paved the way for new
mechanistic investigations on the effects of GM-CSF and IL-3 on the innate immune system. Despite
this growing body of knowledge, several critical questions still remain unanswered. For example, it is
unclear to what extent GM-CSF and IL-3 activities overlap and diverge in vitro and in vivo. Likewise,
most of the efforts have been devoted to characterizing the effects of GM-CSF, with significantly less
examples that have specifically focused the investigation on IL-3. Finally, it is becoming clear that the
contribution of GM-CSF and IL-3 to certain diseases (e.g., IBD) can be context-dependent. Therefore,
it will be critical to define specific patient populations as well as an appropriate time window in which
modulating the activity of these cytokines can lead to clinical benefits.
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